Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated clinical activity and a manageable safety profile in monotherapy and combination therapy clinical trials in relapsed and/or refractory multiple myeloma. CD38 is expressed at high levels on myeloma cells and, to a less...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood Adv
Prif Awduron: Casneuf, Tineke, Xu, Xu Steven, Adams, Homer C., Axel, Amy E., Chiu, Christopher, Khan, Imran, Ahmadi, Tahamtan, Yan, Xiaoyu, Lonial, Sagar, Plesner, Torben, Lokhorst, Henk M., van de Donk, Niels W. C. J., Clemens, Pamela L., Sasser, A. Kate
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2017
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728278/
https://ncbi.nlm.nih.gov/pubmed/29296857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017006866
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg